Skip to main content
Figure 2 | Experimental Hematology & Oncology

Figure 2

From: Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors

Figure 2

Constitutive and immunoproteasome composition in JY cells and BTZ-resistant variants. (A) Relative mRNA levels of constitutive and immunoproteasome subunits in JY/WT and BTZ-resistant variants JY/35BTZ and JY/100BTZ. mRNA levels were normalized relative to β-glucuronidase as house keeping gene. (B) Protein expression of constitutive and immunoproteasome subunits in JY/WT and BTZ-resistant variants JY/35BTZ and JY/100BTZ. (C) Relative protein expression of constitutive and immunoproteasome subunits in JY/WT and BTZ-resistant variants JY/35BTZ and JY/100BTZ. (D) Total constitutive and immunoproteasome subunit expression in JY/WT and BTZ-resistant variants JY/35BTZ and JY/100BTZ. Results depicted are means ± SD of 3–5 separate experiments. *** p < 0.001, ** p < 0.01, * p < 0.05.

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us